OUR MOTIVATION
Bactana isolates molecules expressed from naturally occurring anaerobic bacteria. These molecules are being developed to treat metabolic conditions and digestive disorders. We also develop sustainable products to reduce the use of antibiotics and natural resource during livestock production.
THE MICROBIOME HOLDS THE KEY.
The gut microbiota
plays an essential role in many aspects of life, including metabolism, digestion, and maintenance of a healthy immune system. Molecules produced by commensal bacteria within the gut interact with their animal hosts to support health and suppress a variety of diseases. Bactana has developed a collection of patented product lines based on small molecules isolated from proprietary anaerobic cell lines.
Bactana was formed as a spinoff from Cornell University and began operating from an life science incubator within Cornell’s prestigious McGovern Center in 2017. In 2019 Bactana was honored as the program’s third graduating company.
Currently, Bactana operates from a research laboratory and production facility located Farmington, CT and through its wholly owned subsidiary located in Charlestown Prince Edward Island, Canada.
Our Team.
-
John Kallassy, MBA
CEO & Director
-
Simon McManus, Ph.D.
Head of Research
-
William F. Leimkuhler, JDA
Business Development Advisor
-
Randolph Seidler DVM, Ph.D.
Scientific Advisor & Director
-
DR. SERGE MARTINOD, PH.D., DVM
Scientific Advisor
-
Karel A. Schat, DVM, PhD
Scientific Advisor
"We develop products derived from small molecules expressed by commensal anaerobic bacteria. Our initial product, Pawsni™ Metabolic Health is a therapeutic supplement for pets. Our core technology also shows great promise for human metabolic disease.”
John Kallassy, Bactana’s CEO
